Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Conditions
Keywords
Solid tumors with RET alteration
Brief summary
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene). Participation could last up to 24 months (2 years) and possibly longer if the disease does not get worse.
Interventions
DRUGLOXO-260
Oral
Sponsors
Eli Lilly and Company
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Must be ≥ 18 years of age at the time of signing the informed consent (Phase 1a and Phase 1b). Patients 12 years and older may be enrolled in Phase 1b for countries and sites where approved. * Must have evidence of a previously documented RET fusion (solid tumors) or RET mutation (MTC or MEN2-associated cancers) that is a histological or a cytological proven diagnosis of locally advanced, unresectable and/or metastatic cancer and meet cohort-specific criteria. * Have received a prior selective RET inhibitor. * Eastern Cooperative Oncology Group (ECOG) score of 0 to 1 (age \> 16 years), Karnofsky Performance Status (KPS) ≥ 80 (age \> 16 years), or Lansky Performance Status (LPS) ≥ 40% (age \< 16 years). * Have discontinued all previous treatments for cancer with resolution of any significant AEs, and of all clinically significant toxic effects of prior locoregional therapy, surgery, radiotherapy, or systemic anticancer therapy. * Have adequate organ function. * Phase 1b expansion: Patients must have measurable disease per RECIST v 1.1. * Phase 1b expansion: Molecular Pathology Results (including RET and other genes) from a sample, blood or tissue, taken on or after RET selective treatment.
Exclusion criteria
* Disease suitable for local therapy administered with curative intent. * Have an active fungal, bacterial, and/or active untreated viral infection. * The patient has a serious pre-existing medical condition(s). * Have symptomatic CNS malignancy or metastasis. * Patients treated with drugs known to be strong inhibitors or inducers of cytochrome P450 3A (CYP3A). * Progression of disease within 4 months of starting a prior selective RET inhibitor. * Phase 1b expansion: Patients harboring known activating bypass alterations outside RET that may confer resistance to LOXO-260.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1 a: To determine the MTD/RP2D of LOXO-260: Dose limiting toxicity (DLT) rate | During the first 28-day cycle of LOXO-260 treatment | DLT rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b: To assess the antitumor activity: Overall response rate (ORR) | Up to approximately 24 months or 2 years | ORR per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 |
| To characterize the PK properties of LOXO-260: Mean concentration of LOXO-260 | Up to approximately 24 months or 2 years | PK: Mean concentration of LOXO-260 |
| To assess the antitumor activity of LOXO-260: ORR | Up to approximately 24 months or 2 years | ORR per RECIST 1.1 |
Countries
France, United States
Contacts
STUDY_DIRECTOREmin Avsar
Eli Lilly and Company
Outcome results
None listed